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Abstract
The goal of CERVIS is to make a substantial, positive impact in the cervical cancer diagnostic
space through the development of a minimally invasive, cost effective solution that enables
women in low-resource settings to test for cervical cancer on a frugal and effective platform. In
the developed world, there are a variety of options that can aid in early detection, including pap
smears. However, due to the high cost and laboratory requirements that accompany this
procedure, women in low-resource settings rarely have access to this preventative care or
regular screenings for cervical cancer. Using new research about the changes in the vaginal
microbiome, we aim to create a frugal, visual diagnostic screening tool for early stage cervical
cancer as an alternative to the existing expensive, invasive, and clinic-dependent methods.
Outcomes will be measured by partnering with a Kenyan NGO to collect data from several
clinics.
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Introduction
Cervical Cancer is a global health issue that accounts for 7.5% of all female cancers worldwide
[1]. The World Health Organization estimates that 90% of cervical cancer-related deaths occur in
low and middle income countries, most of which could be prevented by HPV screening and early
diagnosis [2]. Although cervical cancer is the third leading cause of cancer death in women,
there is currently no low-cost, non-invasive screening method available [3]. Early detection of
cervical cancer is crucial to save lives. Early detection can limit the the need for invasive
procedures, significantly increase the chance for successful treatment, and reduce mortality.
Additionally, the link between Human Papillomavirus and cervical cancer has been thoroughly
established. Around one-half of individuals diagnosed with HPV infections have high-risk
infections. HPV 16 and HPV 18, two of the most common strains of high risk HPV cause 70% of
cervical cancers [1].
The goal of the Cervical Cancer Early Response Visual Identification System (CERVIS) is to
detect early stage cervical cancer using changes in the vaginal microbiome during tumorigenesis.
Research on the vaginal microbiome is a relatively new field, and studies show that
Fusobacterium spp. is undetectable in vaginal swabs from a healthy vagina but constitutes
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approximately 17% of bacteria in a vaginal sample from a cervical cancer patient.
Fusobacterium spp. is an anaerobic, gram-negative bacteria usually absent in healthy tissue but
upregulated in instances of disease [4]. Fusobacterium nucleatum is associated with
inflammatory diseases including appendicitis and ulcerative colitis, as well as multiple cancers,
including colorectal, oropharyngeal, and cervical cancers [5].
Studies show no significant difference between the microbial populations between the vagina
and the cervix [6]. For this reason, the use of vaginal sampling instead of cervical sampling was
included in the device design to reduce the dependency on a trained clinician, which is unique
from other cervical cancer detection methods. Women will be able to acquire their own sample
in a non-clinical setting. The goal is to keep CERVIS low cost and minimally invasive to adapt
to the needs of the target population in low resource areas.
The current target population is Kenya, due to the high incidence and mortality rate of cervical
cancer. Cervical cancer ranks as the first most common female cancer in Kenyan women ages 15
to 44 years old with over 5,000 cases diagnosed annually. Kenya also has an extremely high
incidence rate of HPV 16/18, as it is more than double that of the United States and other
developed countries. Currently, 68% of Kenyan women diagnosed with cervical cancer will die
from the disease, making cervical cancer the first leading cause of cancer death in women [7].
Many of these deaths could be prevented by HPV screening and early diagnosis of cervical
cancer; however there is a lack of a low cost, non-invasive diagnostic for low resource settings
[8].
Limitations of current methods Pap smears and colposcopies are the most common methods of cervical screening used in
developed nations to accurately detect both precancerous and cancerous cellular processes within
a swab sample of the cervix [9]. Analysis of pap smears requires a high degree of technical and
clinical knowledge to identify and swab the cervix correctly and analyze sample results and
diagnose accordingly. Additionally, expensive equipment to analyze the sample and the
availability to a laboratory is required for proper and effective analysis. Additionally, these
procedures have a high number of false positives. Finally, on a personal level, pap smears and
colposcopy are invasive, painful, and costly [10].
HPV vaccinations in combination with cancer screenings are the greatest preventative measure
against cervical cancer [11]. FDA approved vaccinations like Gardasil and Cervarix have been
found to be nearly 100% effective at preventing cervical infections of HPV 16/18, the two strains
most commonly associated with the development of cervical cancer. The Center for Disease
Control recommends that all women through the age of 26 and all men through the age of 21 be
vaccinated beginning between the ages of 11-15. While the HPV vaccine provides protection
from HPV infection, it does not offer any therapeutic treatment of the virus or cervical cancer
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[12]. Additionally, social stigmas prevent many from getting vaccinated [13]. The vaccine,
delivered in a three-part series, must be delivered by a health care professional within a clinical
setting, making it difficult for those with limited access to clinics and hospitals to receive the full
dose of the vaccine. Additionally, the vaccine is costly, further creating a barrier to accessing
vaccines in the developing world [13].
Visual Inspection with Acetic Acid (VIA) of the cervix with acetic acid is an effective and
inexpensive screening method in poorly resourced areas [14]. Trained health workers and nurses
work in mobile screening camps in low income areas to perform this diagnostic test. The test is
invasive and can cause some discomfort similar to the pap smear method because of the insertion
of a self-retaining vaginal speculum. After insertion, acetic acid is applied to the cervix and
watched for a reaction between the suspected lesion and the acetic acid [15]. Similar to the
limitations of the previous devices, VIA also requires a high degree of technical knowledge to
properly administer the screening, must be done in a clinical environment, and is highly invasive.
When administering the test, if acetic acid is not applied properly bubbles may still form and
result in false-positives.
Roche CINtec PLUS Cytology is a qualitative immunohistochemistry (IHC) test using the p16
biomarker, which is a cancer biomarker specifically linked to Cervical cancer. The test is
conducted using microscopic assessment of p16INK4a protein in formalin-fixed,
paraffin-embedded (FFPE) cervical punch biopsy tissues. The test confirms cervical
abnormalities based on hematoxylin and eosin (H&E) stained slides. This test is a more specific
alternative to pap smear, but is invasive, expensive, requires a clinician, and results in high rates
of false positives [16].
Table 1: A Comparison Between Current Screening Devices
Device

Benefits

Limitations

Pap smear

Gold standard in developed
nations

Invasive
Expensive
Performed in a clinical setting
Clinical and technical
knowledge required for
analysis

Visual Inspection with Acetic
Acid (VIA)

Inexpensive

Invasive

Primary screening technique
in low resource nations

Moderate technical
knowledge required
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Low sensitivity if
administered incorrectly
Roche CINtec PLUS
Cytology

Specific for Ki-67 and p16
markers of HPV infection

Invasive, Multiple clinic
visits
Specific for >CIN-2

The limitations of these current screening methods highlight the need for a less invasive and
frugal point-of-care diagnostic device. While this device could be used to screen for cervical
cancer in a variety of settings around the world, a device, such as CERVIS, would be particularly
useful for women in low resource settings with limited access to clinics, health professionals, and
other higher-grade medical care.
Methods
Microbial Cultures and Conditions F. Nucleatum ATCC 25586 was streaked for isolation using a disposable sterile loop on
Anaerobe Systems1 Brucella Blood Agar (BRU) and Fusobacterium Selective Agar (FSA).
These plates were incubated at 37 degrees celsius under anaerobic conditions for 48 hours.
Anaerobic conditions were met using an anaerobic chamber, with an internal environment
comprised of 90% N2, 5% CO2, and 5% H2. BRU media was chosen as a positive control,
supporting the growth of Fusobacterium spp. [17]. FSA is an enriched selective medium for the
isolation and presumptive isolation of Fusobacterium species, chosen to inform the formulation
of CERVIS media [18]. The selective character of the FSA media is due to the presence of three
antibiotics: vancomycin, josamycin, and neomycin. The concentrations of each of these
antibiotics inhibit the growth of most other facultative anaerobes [19].
Optimization of Anaerobicity Several cytology applicators- soft bristle brush, polyester swab, and Wallach Papette cervical cell
collector brush- were chosen to measure the amount of oxygen introduced into a semi-solid
media in a closed glass tube. Anaerobe Systems Anaerobic Transport Media AS-911 includes
resazurin, and was used to visually indicate the presence of oxygen in each sample tube. Each
cytology applicator was tested under two conditions. In condition A, the cytology applicator
handle was cut to fit inside the tube and upon inoculation was left in the tube. The cap was
resealed after 15 seconds.In condition B, cytology brushes were inserted into the media and
immediately removed. The cap of the tube was sealed after 15 seconds. Tubes under conditions

produced by Anaerobe Systems is manufactured and packaged in a deoxygenated
environment.
1

Media
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A and B remained sealed at room temperature for 72 hours. Color change, indicated by the redox
reaction of resazurin, was measured after 24, 48, and 72 hours.
CERVIS Media
CERVIS Media was developed as a transparent semi-solid selective media that incorporates the
selective components from Anaerobe Systems’ FSA media, removing blood to facilitate
increased transparency. The CERVIS media was tested in parallel under anaerobic and aerobic
environments. Under both conditions, bristle brush swabs were cut to fit inside the tube. F.
nucleatum cultures were swabbed to obtain isolated colonies. Under anaerobic conditions, tubes
were inoculated, sealed, and placed in the 37 degree incubator for 72 hours inside the anaerobic
chamber. Under aerobic condition, F. nucleatum cultures grown on BRU plates were removed
from the anaerobic chamber and exposed to oxygen prior to inoculation in the CERVIS media.
Tubes were inoculated, sealed, and placed in the 37 degree incubator outside the anaerobic
chamber for 72 hours and monitored for growth.
Results
Media Selectivity
Fusobacterium growth was observed on BRU and FSA. Small, white isolated colonies were
observed after 72 hours. Larger colonies of the same morphology were observed on the BRU
plate than the FSA plate.

Figure 1: F. nucleatum Growth on BRU (left) and FSA (right)
Optimization of Anaerobicity
Table 1 shows oxygen exposure after 72 hours. Oxygen exposure was similar for all swab types
under condition A. Under condition A, the polyester swab and the bristle brush introduced less
oxygen into the system compared to condition B. The cervical cell brush introduced less oxygen
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into the system under condition B. The cervical cell brush did not fit in the tube without size
modification, raising future concerns of contamination and ease of use. The bottom of every tube
does not show presence of oxygen, indicating that an anaerobic bacteria could grow there.
Table 2: Aerobicity Results
Polyester Swab

Bristle Brush

Cervical Cell Brush

AB

AB

AB

CERVIS Media
F. nucleatum growth was observed in CERVIS media under both anaerobic and aerobic
conditions. After 24 hours, regions of concentrated turbidity were observed surrounding the
bristle brush in the bottom of the tube signifying microbial growth. Although growth was visible
after 24 hours, tubes were left in the incubator for 72 hours, checked periodically after 24, 48,
and 72 hours respectively. After 48 and 72 hours, growth was more well defined. Similar
patterns of growth were observed in both anaerobic and aerobic conditions.
Table 3: F. Nucleatum Growth Observed in CERVIS Media
24 hours

48 hours

72 hours
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Discussion
A. Prototype
The results above informed the final design prototype. The prototype includes the glass
anaerobic tube, CERVIS semi-solid selective media, and a sterile soft-bristle brush. This
prototype is designed for ease of use and limits the need for expensive laboratory materials.
Semisolid media was determined as the best choice for the device because it allowed for easy
visualization in a tube while still preventing the diffusion of oxygen when the swab is inserted.
B. Sources of Funding
This project was primarily funded by the Santa Clara University School of Engineering, which
was supplemented with additional funds through the Xilinx grant. These funds were used to fund
the laboratory materials required to conduct research inside the anaerobic chamber. Materials
required for the development of the media and the tube were donated by Anaerobe Systems at
zero cost to the research team. Additional funding is currently being pursued through the
formation of a corporate partnership with a local molecular diagnostic company. Grant funding
through the Massachusetts Medical Society (MMS), the American Medical Women’s
Association (AMWA), and the Adell & Hancock Fund Scholarships are also being investigated
as additional sources of funding to travel to the country of interest to further explore the needs of
the target population.
C. Limitations
One of the primary limitations that comes along with the development of this device is the
difference that exists between in vitro and in vivo results. While we can test fusobacterium s pp.
growth from a culture, it must also be tested with fusobacterium spp. from an infected cervix to
fully understand how the device can be used. The field of vaginal microbiome research is new
and it has only recently gained more attention. There are limited studies about variability and
changes in the microbiome. In order to develop a highly accurate and reliable device, it is
essential to realize that this variability exists. Without some of this knowledge it is difficult to be
able to predict the variability that the device might encounter. For the purpose of the preliminary
experiments conducted, the swabbing procedure was held constant. It is unlikely that these same
conditions will be met after the device is implemented.
Additionally, the Fusobacterium s pp. Requires an incubation temperature of 37 degrees celsius.
Further tests will investigate the minimal temperature requirements and the associated optimal
growth period to attempt to eliminate this criteria. To initially combat this limitation, alternative
incubation methods will be explored to expedite the pilot test including the potential use of
portable neonatal incubators and/or placing one incubator for multiple subjects located in a
central community space [20].
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C. Next steps
Observing Fusobacterium s pp. growth in CERVIS medium proved difficult because these are
non-motile organisms. To improve the visibility of these microbes in CERVIS, the formula
should be altered to include an indicator system. During the next phase of the project, the
primary focus will be on developing a secondary, differential test to confirm the presence of
fusobacterium in the patient’s vaginal microbiome. Fusobacterium spp. p roduces hydrogen
sulfide in the presence of cysteine [21]. Ammonium iron sulfate reacts with hydrogen sulfide
creating a black color change. An iteration of CERVIS media will be developed to include
cysteine and ammonium iron sulfate to trigger the more obvious black color change, making it
easier to visually identify the presence of Fusobacterium spp. [ 22].
Further steps with this project will also work to incorporate a test for high risk HPV. This would
allow the device to not only have the capabilities of detecting early stage cervical cancer, but
also the ability to pick up on high risk HPV infections that are strongly linked to the
development of cervical cancer [23]. Studies show the potential of using other species found in
the vaginal microbiota as an indicator of HPV infection. Sneathia spp. has been described as a
possible microbiological marker of high risk HPV strains associated with the development of
cervical cancer and warrants consideration as a secondary biomarker to increase test specificity
in future device iterations [24].
Partnering with a local NGO in Kenya will help further advance this project to develop an
optimal device deployment and pilot testing strategy. Human subjects research standards and
protocols will be taken. To see the maximum impact, an educational component teaching women
about their anatomy, the risks of cervical cancer, and the importance of screening will be
developed with the help of local community members for ensured cultural relevance and
incorporated into the device implementation strategy. This program will extend to both patients
and providers to increase screening uptake by the women living in the community and minimize
the risk of false positive results. This is an important step in navigating cultural barriers and
ensuring that the device is implemented in the most effective and ethical way.
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